ライフサイエンスコーパス: liquid chromatography-mass spectrometry

1 Resonance spectroscopy and Ultra-Performance Liquid Chromatography Mass Spectrometry.

2 enin, an enamel-forming protein, by nanoflow liquid chromatography mass spectrometry.

3 es by both extraction methods as analyzed by liquid chromatography mass spectrometry.

4 as conducted on extracts of PM samples using liquid chromatography mass spectrometry.

5 nd KC tears (n = 7 KC patients) using tandem-liquid chromatography mass spectrometry.

6 Metabolic profiling was conducted by liquid chromatography-mass spectrometry.

7 ines were measured by ultra-high performance liquid chromatography-mass spectrometry.

8 and cannot be readily separated by standard liquid chromatography-mass spectrometry.

9 Holstein-Friesian and Jersey dairy cattle by liquid chromatography-mass spectrometry.

10 y high-performance liquid chromatography and liquid chromatography-mass spectrometry.

11 ity and compare well to results from NMR and liquid chromatography-mass spectrometry.

12 by partial resistance to restriction and by liquid chromatography-mass spectrometry.

13 Endocannabinoid levels were measured using liquid chromatography-mass spectrometry.

14 rrots on the basis of features determined by liquid chromatography-mass spectrometry.

15 identification of the unmodified analyte by Liquid Chromatography-Mass Spectrometry.

16 each period and analyzed by high-resolution liquid chromatography-mass spectrometry.

17 ts with and 9 without T1R were conducted via liquid chromatography-mass spectrometry.

18 g the growth in presence of vancomycin using liquid chromatography-mass spectrometry.

19 (GlycoStore), exoglycosidase digestions, and liquid chromatography-mass spectrometry.

20 sured plasma lipids and acylcarnitines using liquid chromatography-mass spectrometry.

21 ynamic light scattering, zeta potential, and liquid chromatography-mass spectrometry.

22 ntrations in LS180 cells were assessed using liquid chromatography-mass spectrometry.

23 d with Trypanosoma brucei rhodesiense, using liquid chromatography-mass spectrometry.

24 quantified using UPLC-MS, ultra-performance liquid chromatography-mass spectrometry.

25 easurement of serum phenylacetylglutamine by liquid chromatography-mass spectrometry.

26 were processed and analyzed using label-free liquid chromatography-mass spectrometry.

27 Content of GE was measured by liquid chromatography-mass spectrometry.

28 each A. baumannii strain was measured using liquid chromatography-mass spectrometry.

29 ns of specialized metabolites detected using liquid chromatography-mass spectrometry.

30 actionation of tryptic digests before online liquid chromatography-mass spectrometry.

31 spray mass spectrometry and high-performance liquid chromatography-mass spectrometry.

32 ts, real-time polymerase chain reaction, and liquid chromatography-mass spectrometry.

33 or quantification of TFV-DP and 3TC-TP using liquid chromatography-mass spectrometry.

34 ites were analyzed by gas chromatography and liquid chromatography-mass spectrometry.

35 using trypsin were analyzed by reverse-phase liquid chromatography-mass spectrometry.

36 at the end of each period and analyzed using liquid chromatography-mass spectrometry.

37 ent sets of biological samples analyzed with liquid chromatography-mass spectrometry.

38 rometry, and nonvolatile organic analysis by liquid chromatography/mass spectrometry.

39 y available fluorometric-enzymatic assay and liquid chromatography/mass spectrometry.

40 s were identified by label-free quantitative liquid chromatography/mass spectrometry.

41 h plasma bile acid contents were analyzed by liquid chromatography/mass spectrometry.

42 scle protein fractional synthesis rate using liquid chromatography/mass spectrometry.

43 an online three-dimensional high-performance liquid chromatography/mass spectrometry (3D-HPLC/MS) app

44 For this purpose, a four-dimensional-liquid chromatography/mass spectrometry (4D-LC/MS) metho

45 Liquid chromatography-mass spectrometry analyses identif

46 p. petals were first analyzed using standard liquid chromatography-mass spectrometry analyses of sepa

47 Liquid chromatography mass spectrometry analysis was per

48 Liquid chromatography-mass spectrometry analysis confirm

49 S followed by next-generation sequencing and liquid chromatography-mass spectrometry analysis of the

50 Using high-performance liquid chromatography-mass spectrometry analysis, we det

51 of noncovalently associated peptides during liquid chromatography-mass spectrometry analysis, which

52 The controlled liquid chromatography-mass spectrometry and (18)O-labell

53 cetaminophen concentrations were measured by liquid chromatography-mass spectrometry and C concentrat

54 tochemical fingerprint of bean seeds through liquid chromatography-mass spectrometry and chemometric

55 les were determined by spectrophotometry and liquid chromatography-mass spectrometry and compared wit

56 Hepatic metabolites were measured by liquid chromatography-mass spectrometry and correlated w

57 Effluent analysis by liquid chromatography-mass spectrometry and disk agar bi

58 Whole saliva was analyzed by liquid chromatography-mass spectrometry and gas chromato

59 cally assessed proteolytic degradation using liquid chromatography-mass spectrometry and identified s

60 We also measured total S1P by liquid chromatography-mass spectrometry and isolated HDL

61 cids in cell culture combined with gel-based liquid chromatography-mass spectrometry and lipidome ana

62 Liquid chromatography-mass spectrometry and microarray c

63 D2, D3, D5, E1 and 17-HDHA, were measured by liquid chromatography-mass spectrometry and tested for a

64 reatment were analyzed using high-throughput liquid chromatography-mass spectrometry and were compare

65 ecular formulas of unknown compounds in both liquid chromatography/mass spectrometry and mass spectro

66 n = 60), and healthy controls (n = 30) using liquid chromatography/mass spectrometry and spectrophoto

67 e identified by means of proteomic analysis (liquid chromatography-mass spectrometry) and Ingenuity P

68 ective fraction (30-100 kDa) was analyzed by liquid chromatography-mass spectrometry, and cathepsin D

69 analyzed using gradient ultracentrifugation, liquid chromatography-mass spectrometry, and shotgun lip

70 We performed metabolic profiling using liquid chromatography/mass spectrometry applied to predi

71 s: Elevated PZP was identified by label-free liquid chromatography/mass spectrometry as being associa

72 concentrations were measured using validated liquid chromatography-mass spectrometry assays.

73 D [25(OH)D] with the use of high-performance liquid chromatography-mass spectrometry, assessed dietar

74 an approach that stores the information from liquid chromatography mass spectrometry-based experiment

75 Serum metabolomics was analyzed using a liquid chromatography mass spectrometry-based method.

76 Using aptamer-based proteomics and liquid chromatography-mass spectrometry-based (LC-MS-bas

77 Samples were analyzed using liquid chromatography-mass spectrometry-based metabolomi

78 Ultra-high-performance liquid chromatography-mass spectrometry-based phenolic p

79 Accordingly, ultra-high-performance liquid chromatography-mass spectrometry-based phenolic p

80 ed sugars using a model peptide approach and liquid chromatography-mass spectrometry-based techniques

81 olites associated with VTE risk, we employed liquid chromatography-mass spectrometry-based untargeted

82 Herein, we developed a top-down liquid chromatography/mass spectrometry-based ("LC/MS+")

83 Herein, we present a liquid chromatography/mass spectrometry-based approach f

84 Gas- and liquid chromatography/mass spectrometry-based profiling

85 ed by untargeted metabolomics carried out by liquid-chromatography-mass spectrometry cannot be unique

86 rom several of these phages by high-pressure liquid chromatography-mass spectrometry confirmed that 1

87 Liquid chromatography-mass spectrometry confirmed that t

88 oach for both nuclear magnetic resonance and liquid chromatography-mass spectrometry data from humans

89 Liquid chromatography-mass spectrometry experiments reve

90 ing gas chromatography mass spectrometry and liquid chromatography mass spectrometry for metabolite p

91 ating nanoparticle (NP) protein coronas with liquid chromatography-mass spectrometry for efficient pr

92 hepatic arterial reperfusion and analyzed by liquid chromatography-mass spectrometry for energetic co

93 first time a metabolomics approach based on liquid chromatography-mass spectrometry for revealing su

94 ossible use of a metabolomics approach using liquid chromatography-mass spectrometry for their classi

95 In this work, we report the use of SPME and liquid chromatography-mass spectrometry for untargeted i

96 we analyzed the fatty acyl lipidome of AF by liquid chromatography-mass spectrometry from patients in

97 Untargeted metabolomics by liquid chromatography-mass spectrometry generates data-r

98 UHPLC-MS(n) (Ultra High Performance Liquid Chromatography-Mass Spectrometry) high-throughput

99 troscopy ((1)H NMR), hydrophilic interaction liquid chromatography mass spectrometry (HILIC-MS) and i

100 ample prior to analysis via high-performance liquid chromatography mass spectrometry (HPLC-MS), but a

101 ition assay hyphenated with high performance liquid chromatography-mass spectrometry (HPLC-HRMS).

102 method of direct injection high performance liquid chromatography-mass spectrometry (HPLC-MS) analys

103 tula macrosclereid cells, a high performance liquid chromatography-mass spectrometry (HPLC-MS) assay

104 n for developing a top-down high-performance liquid chromatography-mass spectrometry (HPLC-MS) platfo

105 In the present study, for the first time, liquid chromatography/mass spectrometry (HPLC/MS) was us

106 rations were measured using ultraperformance liquid chromatography mass spectrometry in plasma sample

107 s fractionated and analyzed by high-pressure liquid chromatography-mass spectrometry in order to inve

108 riety of techniques and finally evaluated by liquid chromatography-mass spectrometry in the capillary

109 rooctanoic acid (PFOA) concentrations, using liquid chromatography-mass spectrometry, in 184 colostru

110 antification of 15 mycotoxins in cow milk by liquid chromatography-mass spectrometry, is presented.

111 on the use of comprehensive two-dimensional liquid chromatography mass spectrometry (LC x LC-MS) for

112 ween random amino acid copolymer drugs using liquid chromatography mass spectrometry (LC-MS) analysis

113 ntact monolayer-protected clusters (MPCs) by liquid chromatography mass spectrometry (LC-MS) could pr

114 Chemical isotope labeling (CIL) liquid chromatography mass spectrometry (LC-MS) is a pow

115 a high-performance chemical isotope labeling liquid chromatography mass spectrometry (LC-MS) techniqu

116 based on chemical isotope labeling (CIL) and liquid chromatography mass spectrometry (LC-MS) with a f

117 f phytochemical extracts were acquired using liquid chromatography mass spectrometry (LC-MS), then th

118 omatography mass spectrometry (GC-MS/MS) and liquid chromatography mass spectrometry (LC-MS/MS) were

119 Analysis of oxylipins by liquid chromatography mass spectrometry (LC/MS) is chall

120 ards via the use of stable isotope labeling, liquid chromatography mass spectrometry (LC/MS), and hig

121 e screened for novel acetylation sites using liquid chromatography mass-spectrometry (LC-MS/MS) analy

122 Here using a 96-well plate (liquid chromatography- mass spectrometry (LC-MS) based d

123 ge fraction of ions observed in electrospray liquid chromatography-mass spectrometry (LC-ESI-MS) expe

124 tric waveform ion mobility spectrometry with liquid chromatography-mass spectrometry (LC-FAIMS-MS) ha

125 Liquid chromatography-mass spectrometry (LC-MS) affords

126 bsequent analysis of the residual protein by liquid chromatography-mass spectrometry (LC-MS) after gl

127 ift is underway in the field of quantitative liquid chromatography-mass spectrometry (LC-MS) analysis

128 tion, often however incompatible with direct liquid chromatography-mass spectrometry (LC-MS) analysis

129 The use of liquid chromatography-mass spectrometry (LC-MS) analysis

130 o extract and analyze isotopic patterns from liquid chromatography-mass spectrometry (LC-MS) and gas

131 Metabolite profiling (liquid chromatography-mass spectrometry (LC-MS) and gas

132 We applied high-resolution liquid chromatography-mass spectrometry (LC-MS) and tand

133 A simple and reliable liquid chromatography-mass spectrometry (LC-MS) assay ha

134 ified the levels of each ABX in the brain by liquid chromatography-mass spectrometry (LC-MS) at PND 2

135 Multiple reaction monitoring (MRM) is a liquid chromatography-mass spectrometry (LC-MS) based qu

136 of metabolites remains a major challenge in liquid chromatography-mass spectrometry (LC-MS) based un

137 Analysis of liquid chromatography-mass spectrometry (LC-MS) data req

138 package that takes high resolution wide-scan liquid chromatography-mass spectrometry (LC-MS) data set

139 squares-discriminant analysis (PLS-DA) from liquid chromatography-mass spectrometry (LC-MS) data set

140 he follow up time period clustered, based on liquid chromatography-mass spectrometry (LC-MS) data, wi

141 ak detection and the peak integration in raw liquid chromatography-mass spectrometry (LC-MS) data.

142 Liquid chromatography-mass spectrometry (LC-MS) delivers

143 d solid-phase extraction (MISPE) followed by liquid chromatography-mass spectrometry (LC-MS) for biom

144 on, we aimed at developing a method based on liquid chromatography-mass spectrometry (LC-MS) for the

145 Peptide mapping coupled with liquid chromatography-mass spectrometry (LC-MS) has beco

146 Liquid chromatography-mass spectrometry (LC-MS) has been

147 Affinity capture liquid chromatography-mass spectrometry (LC-MS) intact a

148 A novel liquid chromatography-mass spectrometry (LC-MS) interfac

149 Liquid chromatography-mass spectrometry (LC-MS) is a sta

150 -performance chemical isotope labeling (CIL) liquid chromatography-mass spectrometry (LC-MS) is an en

151 ome based on chemical isotope labeling (CIL) liquid chromatography-mass spectrometry (LC-MS) is repor

152 Liquid chromatography-mass spectrometry (LC-MS) measurem

153 Contrary to the main steps of a typical liquid chromatography-mass spectrometry (LC-MS) metabolo

154 enriched PAHSAs enabled the development of a liquid chromatography-mass spectrometry (LC-MS) method t

155 , a Parallel Reaction Monitoring (PRM)-based liquid chromatography-mass spectrometry (LC-MS) method w

156 Thus, we used stable isotope liquid chromatography-mass spectrometry (LC-MS) methodol

157 P analysis and thereby developed an improved liquid chromatography-mass spectrometry (LC-MS) methodol

158 igosaccharides are characterized by advanced liquid chromatography-mass spectrometry (LC-MS) methods

159 Liquid chromatography-mass spectrometry (LC-MS) methods

160 Liquid chromatography-mass spectrometry (LC-MS) methods

161 e times in the millisecond range for typical liquid chromatography-mass spectrometry (LC-MS) peaks, e

162 ring metabolomics data that are generated by liquid chromatography-mass spectrometry (LC-MS) platform

163 diabetic (n = 6) and healthy (n = 6) dogs by liquid chromatography-mass spectrometry (LC-MS) profilin

164 We employed shotgun liquid chromatography-mass spectrometry (LC-MS) proteomi

165 Label-free peptide quantification in liquid chromatography-mass spectrometry (LC-MS) proteomi

166 Liquid chromatography-mass spectrometry (LC-MS) results

167 titative analysis of total HBM lipids in one liquid chromatography-mass spectrometry (LC-MS) run.

168 Liquid chromatography-mass spectrometry (LC-MS) technolo

169 er dissociation (ETD) on each precursor on a liquid chromatography-mass spectrometry (LC-MS) timescal

170 Liquid chromatography-mass spectrometry (LC-MS) was used

171 Untargeted liquid chromatography-mass spectrometry (LC-MS) was used

172 entified by proteolytic cleavage followed by liquid chromatography-mass spectrometry (LC-MS), but thi

173 phase extraction, followed by analysis using liquid chromatography-mass spectrometry (LC-MS), capilla

174 analysis of fatty acids is undertaken using liquid chromatography-mass spectrometry (LC-MS), due to

175 The results were validated by liquid chromatography-mass spectrometry (LC-MS), exhibit

176 actices for each common analytical platform: liquid chromatography-mass spectrometry (LC-MS), gas chr

177 Using a combination of liquid chromatography-mass spectrometry (LC-MS), size ex

178 hromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS), which d

179 olite identification employ a combination of liquid chromatography-mass spectrometry (LC-MS), which o

180 is a commonly used mobile phase additive in liquid chromatography-mass spectrometry (LC-MS)-based bi

181 In spite of the liquid chromatography-mass spectrometry (LC-MS)-based de

182 Liquid chromatography-mass spectrometry (LC-MS)-based li

183 Liquid chromatography-mass spectrometry (LC-MS)-based me

184 edures for sample collection and processing, liquid chromatography-mass spectrometry (LC-MS)-based me

185 al modifications in a single peptide mapping liquid chromatography-mass spectrometry (LC-MS)-based me

186 sitive strains of P. falciparum by combining liquid chromatography-mass spectrometry (LC-MS)-based pr

187 Liquid chromatography-mass spectrometry (LC-MS)-based pr

188 ntifying the oxidation level by both NMR and liquid chromatography-mass spectrometry (LC-MS).

189 obile phases that are compatible with online liquid chromatography-mass spectrometry (LC-MS).

190 drug-to-antibody ratio (DAR), as measured by liquid chromatography-mass spectrometry (LC-MS).

191 onfirmed in a large cohort of patients using liquid chromatography-mass spectrometry (LC-MS).

192 abeled using the flow system and analyzed by liquid chromatography-mass spectrometry (LC-MS).

193 gel kinase assay (RIKA) with high-resolution liquid chromatography-mass spectrometry (LC-MS).

194 sistent with a conventional ELISA as well as liquid chromatography-mass spectrometry (LC-MS).

195 e analyzed for small molecule metabolites by liquid chromatography-mass spectrometry (LC-MS).

196 e Cancer Cell Line Encyclopedia (CCLE) using liquid chromatography-mass spectrometry (LC-MS).

197 ic deconvolution of high-resolution GC-MS or liquid chromatography-mass spectrometry (LC-MS); and MS-

198 olecularly confirmed PDE were detected using liquid chromatography-mass spectrometry (LC-MS/MS) metho

199 ative and absolute quantitation (iTRAQ) with Liquid chromatography-mass spectrometry (LC-MS/MS) prote

200 hin 1h, and the assay was performed by using liquid chromatography-mass spectrometry (LC-MS/MS) techn

201 In this study, we used liquid chromatography-mass spectrometry (LC-MS/MS) to in

202 oups were analyzed and PyCs quantified using liquid chromatography-mass spectrometry (LC-MS/MS).

203 and reaction products were characterized by liquid chromatography-mass spectrometry (LC-MS/MS).

204 Conventional chiral liquid chromatography-mass spectrometry (LC/MS) HTE meth

205 Due to technical limitations of the Liquid Chromatography-Mass Spectrometry (LC/MS) platform

206 this study, we used low- and high-resolution liquid chromatography-mass spectrometry (LC/MS) techniqu

207 med data-independent, parallel-fragmentation liquid chromatography/mass spectrometry (LC/MS(E)), foll

208 developed X(13)CMS, a platform for analyzing liquid chromatography/mass spectrometry (LC/MS) data at

209 A reversed-phase liquid chromatography/mass spectrometry (LC/MS) methodol

210 Traditional liquid chromatography/mass spectrometry (LC/MS) quantifi

211 lipofuscin fluorophore A2E in the RPE using liquid chromatography/mass spectrometry (LC/MS) showing

212 When using liquid chromatography/mass spectrometry (LC/MS) to perfo

213 line, hosted on the LIPID MAPS website, as a liquid chromatography/mass spectrometry (LC/MS) workflow

214 within a biological system, most commonly by liquid chromatography/mass spectrometry (LC/MS).

215 ompounds, previously done with accurate mass liquid chromatography/mass spectrometry (LC/MS).

216 With the developed liquid-chromatography mass spectrometry (LC-MS) lipidomi

217 In this study we demonstrate that liquid-chromatography-mass spectrometry (LC-MS) can be u

218 Untargeted liquid-chromatography-mass spectrometry (LC-MS)-based me

219 High Performance Liquid Chromatography - Mass Spectrometry/Mass Spectrome

220 tensin analysis was performed using a unique liquid chromatography-mass spectrometry/mass spectroscop

221 n peptide profiles were assessed using novel liquid chromatography-mass spectrometry/mass spectroscop

222 mbining state-of-the-art ultra-high-pressure liquid chromatography-mass spectrometry metabolic flux a

223 1N1 infection responses, we performed global liquid chromatography-mass spectrometry metabolic profil

224 A promising approach for mining liquid chromatography-mass spectrometry metabolite profi

225 As such, we applied an untargeted liquid chromatography-mass spectrometry metabolomic stra

226 Our pilot study using liquid chromatography-mass spectrometry metabolomics ana

227 Here, we performed nontargeted liquid chromatography-mass spectrometry metabolomics to

228 Untargeted liquid chromatography-mass spectrometry metabolomics was

229 = 45) from Bangladesh using high-resolution liquid chromatography-mass spectrometry metabolomics.

230 By using targeted liquid chromatography/mass spectrometry metabolomics, we

231 An accurate, simple and rapid liquid chromatography mass spectrometry method for the d

232 A liquid chromatography-mass spectrometry method was devel

233 We developed a high-resolution liquid chromatography/mass spectrometry method and deter

234 Recent advances in liquid chromatography-mass spectrometry methods have ena

235 riety of analytical tools, including gas and liquid chromatography, mass spectrometry (MS), and nucle

236 In nano-liquid chromatography-mass spectrometry (nano-LC-ESI-MS)

237 nce chemical isotope labeling (CIL) nanoflow liquid chromatography mass spectrometry (nanoLC-MS) for

238 counterterrorism purposes, a selective nano liquid chromatography-mass spectrometry (nanoLC-MS) plat

239 We describe a robust nano liquid chromatography-mass spectrometry (nanoLC-MS) plat

240 the glycolipids is performed using nanoflow liquid chromatography-mass spectrometry (nanoLC-MS).

241 BA profiling and quantification by liquid chromatography-mass spectrometry of serum, gallbl

242 istry and electron microscopy, and performed liquid chromatography-mass spectrometry on optic gliomas

243 -nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry or urine and fec

244 files were analyzed by ultrahigh-performance liquid chromatography-mass spectrometry over a period of

245 data generated from bottom-up proteomics via liquid chromatography-mass spectrometry, particularly fo

246 in fatty acids (SCFAs) were measured using a liquid chromatography-mass spectrometry platform.

247 -based instruments, and (iii) high flow rate liquid chromatography mass spectrometry platforms.

248 ids are analyzed using an optimized nanoflow liquid chromatography/mass spectrometry protocol.

249 Liquid chromatography/mass spectrometry quantified BAs.

250 re measured with the use of immunoassays and liquid chromatography-mass spectrometry, respectively, i

251 ELISA, and urinary fumonisin B1 (UFB1) using liquid chromatography-mass spectrometry, respectively.

252 quantitative polymerase chain reaction, and liquid chromatography-mass spectrometry revealed a highe

253 Analysis of fractions by liquid chromatography-mass spectrometry revealed reliabl

254 the PWGPE was determined by rapid resolution liquid chromatography/mass spectrometry (RRLC/MS).

255 We developed an unbiased liquid chromatography-mass spectrometry screen for enzym

256 Through liquid chromatography-mass spectrometry screening of int

257 g high-performance liquid chromatography and liquid chromatography-mass spectrometry showed that capt

258 of the compounds using ultrahigh-performance liquid chromatography-mass spectrometry-solid-phase extr

259 ative and absolute quantitation-labeling and liquid chromatography-mass spectrometry, tandem mass spe

260 In the present work, we developed a liquid chromatography/mass spectrometry targeted assay,

261 in cows over the entire milking season using liquid chromatography-mass spectrometry technique.

262 With the use of liquid chromatography-mass spectrometry-time-of-flight a

263 Aqueous seed extracts were found by liquid chromatography mass spectrometry to contain selen

264 s to small oligosaccharides followed by fast liquid chromatography mass spectrometry to determine sam

265 of plasma metabolites using ultraperformance liquid chromatography mass spectrometry to identify pati

266 Here, we use liquid chromatography mass spectrometry to provide a com

267 We employed liquid chromatography mass spectrometry to search for th

268 We used liquid chromatography-mass spectrometry to analyze plasm

269 We also used liquid chromatography-mass spectrometry to characterize

270 tablish that BONCAT can be coupled to tandem liquid chromatography-mass spectrometry to identify and

271 oligonucleotide affinity chromatography and liquid chromatography-mass spectrometry to identify nucl

272 roliquid extraction for surface analysis and liquid chromatography-mass spectrometry to locate sterol

273 The method uses liquid chromatography-mass spectrometry to monitor the r

274 hly efficient 3-dimensional high performance liquid chromatography/mass spectrometry to enable quanti

275 lldown assays combined with high sensitivity liquid chromatography/mass spectrometry to identify nove

276 Using liquid chromatography-mass spectrometry, to our knowledg

277 ght scattering (DLS) and ultra high pressure liquid chromatography-mass spectrometry (UHPLC-MS), we s

278 crodialysis is coupled with ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) analys

279 r standard methods such as Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) and En

280 Hyphenated ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) has be

281 A rapid gradient microbore ultraperformance liquid chromatography-mass spectrometry (UPLC-MS) method

282 rences were analyzed using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) of sam

283 The ultra performance liquid chromatography-mass spectrometry (UPLC-MS)/MS tar

284 An ultra performance liquid chromatography-mass spectrometry (UPLC-MS/MS) met

285 24 adults were analyzed by ultra-performance liquid chromatography/mass spectrometry (UPLC-MS).

286 thout late-onset T2D using ultra-performance liquid-chromatography mass-spectrometry (UPLC-MS) to ide

287 Liquid chromatography-mass spectrometry was used to dete

288 Comprehensive metabolomics analysis with liquid chromatography-mass spectrometry was used to dete

289 ip with disease severity.Methods: Label-free liquid chromatography/mass spectrometry was performed fo

290 High performance liquid chromatography/mass spectrometry was used to conf

291 mino acids in cell culture and reverse-phase liquid chromatography mass spectrometry, we assessed the

292 Using liquid chromatography-mass spectrometry, we analyzed 304

293 Using liquid chromatography-mass spectrometry, we have analyze

294 Using immunoaffinity liquid chromatography-mass spectrometry, we identified a

295 Using liquid chromatography-mass spectrometry, we measured 25(

296 Using two-dimensional electrophoresis and liquid chromatography-mass spectrometry, we studied APOE

297 Via liquid chromatography/mass spectrometry, we measured inc

298 racers measured by quadrupole time-of-flight liquid chromatography-mass spectrometry were used to qua

299 Gas and ultra-high performance liquid chromatography/mass spectrometry were used in met

300 ens a new opportunity for spatially resolved liquid chromatography mass spectrometry with precision b